HOME >> BIOLOGY >> NEWS
UB Fertility Researchers Find They Can Predict Pregnancy By Assessing Two Sperm Abnormalities

SAN DIEGO, Calif. -- Fertility researchers at the University at Buffalo School of Medicine and Biomedical Sciences have found a link between specific clinical pregnancies and very low levels of two sperm abnormalities.

The two abnormalities -- premature chromosomal decondensation and premature acrosome reaction, which are overlooked in a standard semen analysis -- had never been linked to low pregnancy rates, said Lani J. Burkman, Ph.D., UB assistant professor of gynecology and obstetrics, and urology, and head of the Andrology Section of the UB Department of Gynecology-Obstetrics.

By analyzing hundreds of semen samples and comparing them with subsequent pregnancies in the couples studied, Burkman and colleagues determined that samples showing more than 14 percent premature chromosomal decondensation or more than 7 percent premature acrosome reactions had only a slim chance of leading to a pregnancy.

"We were surprised to see that these two factors related to pregnancy so clearly," said Burkman, lead researcher on the study. "This is a new finding, and it's impressive because the test is so simple."

Burkman will present results of the study today (June 2) at the meeting of the American Urology Association.

The acrosome is a enzyme-filled cap covering half the sperm head. Just before fertilization, enzymes from the acrosome, activated at the proper time, soften the egg's covering, or zona, allowing the sperm head with its genetic material to fertilize the egg. If the enzymes are released too soon, a process called premature acrosome reaction, the sperm is rendered useless.

Premature chromosomal decondensation refers to the untimely unraveling of the sperm's tightly packed genetic cargo. If this begins before the sperm has penetrated the egg, the sperm head swells and fertilization becomes impossible.

"In our study, when pregnancy occurred, we knew that the partner's sperm were capable of fertilizing
'"/>

Contact: Lois Baker
baker@newsb.buffalo.edu
716-645-2626
University at Buffalo
29-May-1998


Page: 1 2

Related biology news :

1. Fertility study shows increased estrogen shortens window of implantation in mice
2. Fertility treatments increase incidence of twins at a cost
3. Fertility experts urge clinics to consider natural cycle IVF instead of routine use of ovarian stimulants
4. Discovery Of Mutation May Lead To Help For Male Fertility Problems
5. Research Suggests New Way To Gauge A Womans Fertility
6. Sperm Protein May Hold Clues For Fertility And Contraceptives
7. Poetically Timed With Spring, Budding Yeast Yield Possible Insight Into Male Fertility--And Infertility
8. Discovery By Fertility Specialist Offers Promise Of Reducing Multiple BirthsTied To Fertility Treatment
9. Researchers determine genetic cause of Timothy syndrome
10. Researchers find color sensitive atomic switch in bacteria
11. Researchers identify protein promoting vascular tumor growth

Post Your Comments:
(Date:2/24/2015)... DUBLIN , Feb. 24, 2015 Research ... announced the addition of the "Global 2D ... offering. The analysts forecast the ... a CAGR of 32.12% over the period 2014-2019 ... devices in non-traditional sectors is one of the ...
(Date:2/13/2015)... -- ACT Genomics Co., Ltd., a cancer molecular ... genomic information into precision diagnosis and personalized treatments, ... million in the its first private funding round. ... , ACT Genomics has developed comprehensive cancer ... implement next generation sequencing (NGS) and multiplex molecular ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
(Date:2/27/2015)... 2015 A paper published today, " ... " in Science Translational Medicine, demonstrates ... reduce the risk associated with investing in the ... levels of funding for developing so-called "orphan" drugs. ... collaboration between scientists at the National Center for ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
Cached News: